Sangamo Therapeutics (SGMO) Reaches $7.88 After 4.00% Up Move; Watsco (WSO) Sentiment Is 1.23

June 19, 2017 - By Clifton Ray

Watsco, Inc. is a distributor of air conditioning, heating and refrigeration equipment, and related parts and supplies in the HVAC/R distribution industry in North America. The company has market cap of $5.37 billion. As of December 31, 2016, the Company sold a range of non-equipment products, representing more than 300,000 stock keeping units, including parts, ductwork, air movement products, insulation, tools, installation supplies, thermostats and air quality products. It has a 29.39 P/E ratio. It distributes products consisting of equipment, including residential ducted and ductless air conditioners ranging from 1 to 5 tons, gas, electric and oil furnaces ranging from 50,000 to 150,000 British Thermal Units, commercial air conditioning and heating equipment and systems ranging from 1.5 to 25 tons and other specialized equipment; parts, including replacement compressors and motors, and supplies, including ductwork, grills, registers, sheet metal, adhesives and other ancillary supplies.

The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) is a huge mover today! About 323,895 shares traded. Sangamo Therapeutics Inc (NASDAQ:SGMO) has risen 29.78% since June 19, 2016 and is uptrending. It has outperformed by 13.08% the S&P500.The move comes after 5 months positive chart setup for the $578.26 million company. It was reported on Jun, 19 by We have $8.20 PT which if reached, will make NASDAQ:SGMO worth $23.13 million more.

Since May 11, 2017, it had 0 insider purchases, and 2 sales for $34,754 activity. 2,639 Sangamo Therapeutics Inc (NASDAQ:SGMO) shares with value of $21,154 were sold by Herberts Curt A. III.

Investors sentiment decreased to 1.15 in 2016 Q4. Its down 0.06, from 1.21 in 2016Q3. It dived, as 17 investors sold Sangamo Therapeutics Inc shares while 31 reduced holdings. 18 funds opened positions while 37 raised stakes. 39.96 million shares or 8.31% less from 43.58 million shares in 2016Q3 were reported. Blackrock accumulated 5,224 shares. Columbus Circle holds 440,428 shares or 0.02% of its portfolio. 49,200 are held by Bourgeon Cap Limited Company. Princeton Cap Mgmt reported 44,250 shares. Princeton Alpha Mgmt L P stated it has 36,126 shares. Us Comml Bank De holds 5,000 shares. Transamerica has 0% invested in Sangamo Therapeutics Inc (NASDAQ:SGMO). Moreover, Cormorant Asset has 0.27% invested in Sangamo Therapeutics Inc (NASDAQ:SGMO) for 650,000 shares. Blackrock Advsrs Ltd Liability Corporation owns 213,766 shares for 0% of their portfolio. Geode Capital Mngmt Limited Liability Co holds 614,633 shares or 0% of its portfolio. Fifth Third Bancshares holds 0% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO) for 400 shares. 43,008 are held by Leisure Management. State Board Of Administration Of Florida Retirement reported 61,070 shares. Natl Bank Of Montreal Can stated it has 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Goldman Sachs Gp holds 0% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO) for 174,455 shares.

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The company has market cap of $578.26 million. The Firm is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. It currently has negative earnings. The Firm has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development.

Among 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 have Buy rating, 1 Sell and 4 Hold. Therefore 44% are positive. Sangamo Biosciences had 12 analyst reports since August 8, 2015 according to SRatingsIntel. The rating was downgraded by Piper Jaffray to “Neutral” on Wednesday, October 19. The rating was downgraded by Zacks to “Sell” on Tuesday, September 8. As per Friday, September 4, the company rating was maintained by Cowen & Co. The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) has “Overweight” rating given on Saturday, August 8 by JP Morgan. Wedbush maintained the stock with “Buy” rating in Wednesday, September 2 report. Jefferies reinitiated Sangamo Therapeutics Inc (NASDAQ:SGMO) on Friday, October 23 with “Buy” rating. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. On Wednesday, October 19 the stock rating was downgraded by PiperJaffray to “Neutral”. The firm has “Buy” rating by Jefferies given on Wednesday, September 2. The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) earned “Neutral” rating by Wedbush on Tuesday, November 1.

Analysts await Watsco Inc (NYSE:WSO) to report earnings on July, 28. They expect $2.02 earnings per share, up 10.99% or $0.20 from last year’s $1.82 per share. WSO’s profit will be $71.90 million for 18.67 P/E if the $2.02 EPS becomes a reality. After $0.67 actual earnings per share reported by Watsco Inc for the previous quarter, Wall Street now forecasts 201.49% EPS growth.

Ratings analysis reveals 67% of Watsco’s analysts are positive. Out of 3 Wall Street analysts rating Watsco, 2 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. WSO was included in 3 notes of analysts from October 14, 2016. The stock has “Underweight” rating by Morgan Stanley on Tuesday, December 20. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, February 15 report. Longbow upgraded the shares of WSO in report on Friday, October 14 to “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: